TRANSCEND CAPITAL ADVISORS, LLC

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 1776082 MADISON, NJ

Position in VRTX

as of Jun 30, 2026 · filed Aug 4, 2026 Compact

Position Value

$1,475,784

+$358,095 QoQ

Shares Held

2,971

+18.7% QoQ

Ownership

0.001%

of shares outstanding

% of Portfolio

0.14%

of 13F equity value

Holder Rank

#751

of 1,735 holders

Holding Since

Dec 2022

10 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

TRANSCEND CAPITAL ADVISORS, LLC holds $6,758,569 across 9 Biotechnology names. VRTX ranks #2 (21.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	KRYS	Krystal Biotech, Inc.	6,522	$2,424,031
2	VRTX	Vertex Pharmaceuticals Inc / Ma This page	2,971	$1,475,784
3	INCY	Incyte Corp	8,231	$933,066
4	REGN	Regeneron Pharmaceuticals, Inc.	901	$561,809
5	TGTX	Tg Therapeutics, Inc.	8,658	$475,670
6	EXEL	Exelixis, Inc.	6,283	$341,858
7	CLDX	Celldex Therapeutics, Inc.	6,196	$230,553
8	BMRN	Biomarin Pharmaceutical Inc	3,912	$223,844

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$1,475,784	2,971	+18.7%	Shares	Sole	2026-08-04
2026-03-31	$1,117,689	2,503	+24.3%	Shares	Sole	2026-05-13
2025-12-31	$912,613	2,013	-21.7%	Shares	Sole	2026-01-23
2025-09-30	$1,007,298	2,572	+47.5%	Shares	Sole	2025-11-04
2025-06-30	$776,428	1,744	-46.6%	Shares	Sole	2025-08-01
2025-03-31	$1,583,422	3,266	+0.3%	Shares	Sole	2025-04-24
2024-12-31	$1,311,191	3,256	+36.7%	Shares	Sole	2025-02-03
2024-09-30	$1,107,355	2,381	+49.2%	Shares	Sole	2024-10-15
2024-06-30	$748,077	1,596	+95.6%	Shares	Sole	2024-07-02
2022-12-31	$235,644	816	—	Shares	Sole	2023-01-20
No filing history on record for this holder in this stock.